Bausch + Lomb Corporation (TSX:BLCO)
Canada
· Delayed Price · Currency is CAD 16.59
+0.05 (0.30%)
May 13, 2025, 10:25 AM EDT
Revenue by Product
Fiscal year is January - December.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Vision Care | 2.76B |
Log In |
Log In |
Log In |
Log In |
| Vision Care Growth | 6.52% |
Log In |
Log In |
Log In |
Log In |
| Surgical | 860.00M |
Log In |
Log In |
Log In |
Log In |
| Surgical Growth | 10.12% |
Log In |
Log In |
Log In |
Log In |
| Ophthalmic Pharmaceuticals | 1.21B |
Log In |
Log In |
Log In |
Log In |
| Ophthalmic Pharmaceuticals Growth | 28.34% |
Log In |
Log In |
Log In |
Log In |
| Pharmaceuticals | 982.00M |
Log In |
Log In |
Log In |
Log In |
| Pharmaceuticals Growth | 36.58% |
Log In |
Log In |
Log In |
Log In |
| Devices | 1.82B |
Log In |
Log In |
Log In |
Log In |
| Devices Growth | 9.35% |
Log In |
Log In |
Log In |
Log In |
| OTC | 1.74B |
Log In |
Log In |
Log In |
Log In |
| OTC Growth | 5.14% |
Log In |
Log In |
Log In |
Log In |
| Branded and Other Generics | 269.00M |
Log In |
Log In |
Log In |
Log In |
| Branded and Other Generics Growth | 4.67% |
Log In |
Log In |
Log In |
Log In |
| Total Product | 4.81B |
Log In |
Log In |
Log In |
Log In |
| Total Product Growth | 12.01% |
Log In |
Log In |
Log In |
Log In |
| Other Product | 16.00M |
Log In |
Log In |
Log In |
Log In |
| Other Product Growth | -5.88% |
Log In |
Log In |
Log In |
Log In |
Capex by Product
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Vision Care Capital Expenditures |
Log In |
Log In |
Log In |
Log In |
| Vision Care Capital Expenditures Growth |
Log In |
Log In |
Log In |
Log In |
| Surgical Segment Expenditures |
Log In |
Log In |
Log In |
Log In |
| Surgical Segment Expenditures Growth |
Log In |
Log In |
Log In |
Log In |
| Ophthalmic Pharmaceuticals Capital Expenditures |
Log In |
Log In |
Log In |
Log In |
| Ophthalmic Pharmaceuticals Capital Expenditures Growth |
Log In |
Log In |
Log In |
Log In |
| Corporate Capital Expenditures |
Log In |
Log In |
Log In |
Log In |
| Corporate Capital Expenditures Growth |
Log In |
Log In |
Log In |
Log In |
EBIT by Product
Fiscal year is January - December.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Vision Care Segment Profit | 806.00M |
Log In |
Log In |
Log In |
Log In |
| Vision Care Segment Profit Growth | 13.04% |
Log In |
Log In |
Log In |
Log In |
| Surgical Segment Profit | 26.00M |
Log In |
Log In |
Log In |
Log In |
| Surgical Segment Profit Growth | -48.00% |
Log In |
Log In |
Log In |
Log In |
| Ophthalmic Pharmaceuticals Segment Profit | 214.00M |
Log In |
Log In |
Log In |
Log In |
| Ophthalmic Pharmaceuticals Segment Profit Growth | -13.71% |
Log In |
Log In |
Log In |
Log In |
| Corporate Segment Profit | -635.00M |
Log In |
Log In |
Log In |
Log In |
| Corporate Segment Profit Growth | 17.16% |
Log In |
Log In |
Log In |
Log In |
| Amortization of Intangible Assets | -281.00M |
Log In |
Log In |
Log In |
Log In |
| Amortization of Intangible Assets Growth | 9.34% |
Log In |
Log In |
Log In |
Log In |
| Net Other Expense | -57.00M |
Log In |
Log In |
Log In |
Log In |
| Net Other Expense Growth | -22.97% |
Log In |
Log In |
Log In |
Log In |
Revenue by Geography
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| U.S. and Puerto Rico |
Log In |
Log In |
Log In |
Log In |
| U.S. and Puerto Rico Growth |
Log In |
Log In |
Log In |
Log In |
| Total International |
Log In |
Log In |
Log In |
Log In |
| Total International Growth |
Log In |
Log In |
Log In |
Log In |
Other
Fiscal year is January - December.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Vision Care Revenue Organic Change | - |
Log In |
Log In |
Log In |
Log In |
| Vision Care Revenue Organic Change Growth | - |
Log In |
Log In |
Log In |
Log In |
| Ophthalmic Pharmaceuticals Revenue Organic Change | - |
Log In |
Log In |
Log In |
Log In |
| Ophthalmic Pharmaceuticals Revenue Organic Change Growth | - |
Log In |
Log In |
Log In |
Log In |
| Surgical Revenue Organic Change | - |
Log In |
Log In |
Log In |
Log In |
| Surgical Revenue Organic Change Growth | - |
Log In |
Log In |
Log In |
Log In |
| Total Revenue Organic Change | - |
Log In |
Log In |
Log In |
Log In |
| Total Revenue Organic Change Growth | - |
Log In |
Log In |
Log In |
Log In |
| Vision Care Revenue Change in Constant Currency | - |
Log In |
Log In |
Log In |
Log In |
| Vision Care Revenue Change in Constant Currency Growth | -21.43% |
Log In |
Log In |
Log In |
Log In |
| Surgical Revenue Change in Constant Currency | - |
Log In |
Log In |
Log In |
Log In |
| Surgical Revenue Change in Constant Currency Growth | 67.86% |
Log In |
Log In |
Log In |
Log In |
| Total Revenue Change in Constant Currency | - |
Log In |
Log In |
Log In |
Log In |
| Total Revenue Change in Constant Currency Growth | -6.78% |
Log In |
Log In |
Log In |
Log In |
| Ophthalmic Pharmaceuticals Revenue Change in Constant Currency | - |
Log In |
Log In |
Log In |
Log In |
| Ophthalmic Pharmaceuticals Revenue Change in Constant Currency Growth | -2.68% |
Log In |
Log In |
Log In |
Log In |